Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury

Gene Therapy

Volumn 16, Issue 1, 2009, Pages 26-33

  Kato, R ^a,b   Wolfe, D ^a,c   Coyle, C H ^a   Wechuck, J B ^a,c   Tyagi, P ^a   Tsukamoto, T ^b   Nelson, J B ^a   Glorioso, J C ^a   Chancellor, M B ^a   Yoshimura, N ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Diamyd Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HERPESVIRUS VECTOR; NEURTURIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CAVERNOUS NERVE INJURY; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; ERECTILE DYSFUNCTION; HERPES SIMPLEX VIRUS; MALE; NERVE INJURY; NERVE REGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BIOLOGICAL MARKERS; ERECTILE DYSFUNCTION; GANGLIA, SPINAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; MODELS, ANIMAL; NERVE REGENERATION; NEURTURIN; NITRIC OXIDE SYNTHASE TYPE I; PENIS; RATS; RATS, SPRAGUE-DAWLEY; SIMPLEXVIRUS; TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE;

RATTUS; SIMPLEXVIRUS;

EID: 58149462239     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.132     Document Type: Article

References (50)

1. Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR et al. Patient reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997; 89: 1117-1123.
2. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164: 1929-1934.
3. Shimizu T, Hisasue S, Sato Y, Kato R, Kobayashi K, Tsukamoto T. Erectile dysfunction following nerve-sparing radical retropubic prostatectomy and its treatment with sildenafil. Int J Urol 2005; 12: 552-557.
4. Quinlan DM, Nelson RJ, Walsh PC. Cavernous nerve grafts restore erectile function in denervated rats. J Urol 1991; 145: 380-383.
5. Hisasue S, Kato R, Sato Y, Suetomi T, Tabata Y, Tsukamoto T. Cavernous nerve reconstruction with a biodegradable conduit graft and collagen sponge in the rat. J Urol 2005; 173: 286-291.
6. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7: 1073-1074.
7. Hayashi N, Minor TX, Carrion R, Price R, Nunes L, Lue TF. The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model. J Urol 2006; 176: 824-829.
8. Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol 2005; 174: 2060-2064.
9. Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int 2004; 94: 904-909.
10. Kendirci M, Zsengeller Z, Bivalacqua TJ, Gur S, Usta MF, Chen M et al Poly (Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury. J Urol 2005; 174: 2054-2059.
11. Chen KC, Minor TX, Rahman NU, Ho HC, Nunes L, Lue TF. The additive erectile recovery effect of brain-derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotence. BJU Int 2005; 95: 1077-1080.
12. Bochinski D, Hsieh PS, Nunes L, Lin GT, Lin CS, Spencer EM et al. Effect of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 complex in cavernous nerve cryoablation. Int J Impot Res 2004; 16: 418-423.
13. Bivalacqua TJ, Deng W, Champion HC, Hellstrom WJ, Kadowitz PJ. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpora cavernosa for erectile dysfunction. Methods Mol Biol 2004; 279: 173-185.
14. Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J et al Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod 2002; 67: 1033-1041.
15. Christ GJ, Day N, Santizo C, Sato Y, Zhao W, Sclafani T et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol 2004; 287: H1544-H1553.
16. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: Preliminary results. Eur Urol 2005; 48: 314-318.
17. Laurikainen A, Hiltunen JO, Thomas-Crusells J, Vanhatalo S, Arumae U, Airaksinen MS et al. Neurturin is a neurotrophic factor for penile parasympathetic neurons in adult rat. J Neurobiol 2000; 43: 198-205.
18. Wanigasekara Y, Airaksinen MS, Heuckeroth RO, Milbrandt J, Keast JR. Neurturin signalling via GFRalpha2 is essential for innervation of glandular but not muscle targets of sacral parasympathetic ganglion neurons. Mol Cell Neurosci 2004; 25: 288-300.
19. Wanigasekara Y, Keast JR. Neurturin has multiple neurotrophic effects on adult rat sacral parasympathetic ganglion neurons. Eur J Neurosci 2005; 22: 595-604.
20. Palma CA, Keast JR. Structural effects and potential changes in growth factor signalling in penis-projecting autonomic neurons after axotomy. BMC Neurosci 2006; 7: 41.
21. Hisasue S, Kato R, Suetomi T, Kato K, Suzuki K, Kobayashi K et al. Age-related alteration of neurturin receptor GFRa2 and nNOS in pelvic ganglia. Neurobiol Aging 2006; 27: 1524-1530.
22. Bella AJ, Fandel TM, Tantiwongse K, Brant WO, Klein RD, Garcia CA et al. Neurturin enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J Brachial Plex Peripher Nerve Inj 2007; 6: 2-5.
23. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695-702.
24. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284: 2215-2221.
25. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994; 36: 244-246.
26. Thoenen H, Sendtner M. Neurotrophins: From enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002; 5: 1046-1050.
27. Samaniego L, Webb A, DeLuca N. Functional interaction between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995; 69: 5705-5715.
28. Samaniego L, Naxin W, DeLuca N. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71: 4614-4625.
29. Marconi P, Krisky D, Oligino T, Poliani PL, Ramakrishnan R, Goins WF et al. Replication-defective HSV vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996; 93: 11319-11320.
30. Krisky D, Marconi P, Oligino T, Rouse R, Fink D, Glorioso J. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Therapy 1997; 4: 1120-1125.
31. Jiang C, Wechuck JB, Goins WF, Krisky DM, Wolfe D, Ataai MM et al. Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J Virol 2004; 78: 8994-9006.
32. Ozuer A, Wechuck JB, Russell B, Wolfe D, Goins WF, Glorioso JC et al Evaluation of infection parameters in the production of replication-defective HSV-1 viral vectors. Biotechnol Prog 2002; 18: 476-482.
33. Ozuer A, Wechuck JB, Goins WF, Wolfe D, Glorioso JC, Ataai MM. Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol Bioeng 2002; 77: 685-692.
34. Goins WF, Yoshimura N, Phelan MW, Yokoyama T, Fraser MO, Ozawa H et al. Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: Potential treatment for diabetic bladder dysfunction. J Urol 2001; 165: 1748-1754.
35. Sasaki K, Chancellor MB, Goins WF, Phelan MW, Glorioso JC, de Groat WC et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 2004; 53: 2723-2730.
36. Bennett NE, Kim JH, Wolfe DP, Sasaki K, Yoshimura N, Goins WF et al Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005; 173: 1820-1824.
37. Hao S, Mata M, Wolfe D, Huang S, Glorioso JC, Fink DJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol 2005; 57: 914-918.
38. Chattopadhyay M, Goss J, Wolfe D, Goins WC, Huang S, Glorioso JC et al. Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain 2004; 127: 929-939.
39. Chattopadhyay M, Wolfe D, Huang S, Goss J, Glorioso JC, Mata M et al. In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3. Ann Neurol 2002; 51: 19-27.
40. Chattopadhyay M, Goss J, Lacomis D, Goins WC, Glorioso JC, Mata M et al. Protective effect of HSV-mediated gene transfer of nerve growth factor in pyridoxine neuropathy demonstrates functional activity of trkA receptors in large sensory neurons of adult animals. Eur J Neurosci 2003; 17: 732-740.
41. Natsume A, Mata M, Wolfe D, Oligino T, Goss J, Huang S et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect. J Neurotrauma 2002; 19 61-68.
42. Natsume A, Wolfe D, Hu J, Huang S, Puskovic V, Glorioso JC et al. Enhanced functional recovery after proximal nerve root injury by vector-mediated gene transfer. Exp Neurol 2003; 184: 878-886.
43. Kato R, Wolfe D, Coyle CH, Huang S, Wechuck JB, Goins WF et al. Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Therapy 2007; 14: 1344-1352.
44. Jung GW, Spencer EM, Lue TF. Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats. J Urol 1998; 160: 1899-1904.
45. Tamura M, Kagawa S, Tsuruo Y, Ishimura K, Kimura K, Kawanishi Y. Localization of NADPH diaphorase and vasoactive intestinal polypeptide-containing neurons in the efferent pathway to the rat corpus cavernosum. Eur Urol 1997; 32: 100-104.
46. Kato R, Kiryu-Seo S, Sato Y, Hisasue S, Tsukamoto T, Kiyama H. Cavernous nerve injury elicits GAP-43 mRNA expression but not regeneration of injured pelvic ganglion neurons. Brain Res 2003; 986: 166-173.
47. Matsuura S, Obara T, Tsuchiya N, Suzuki Y, Habuchi T. Cavernous nerve regeneration by biodegradable alginate gel sponge sheet placement without sutures. Urology 2006; 68: 1366-1371.
48. Xiao H, Hirata Y, Isobe K, Kiuchi K. Glial cell line-derived neurotrophic factor up-regulates the expression of tyrosine hydroxylase gene in human neuroblastoma cell lines. J Neurochem 2002; 82 801-808.
49. Chen X, Li J, Mata M, Goss J, Wolfe D, Glorioso JC et al. Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J Virol 2000; 74: 10132-10141.
50. Chuang YC, Fraser MO, Yu Y, Beckel JM, Seki S, Nakanishi Y et al. Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1302-R1310.